Autoantibodies to N-terminally Truncated GAD65(96-585): HLA Associations and Predictive Value for Type 1 Diabetes
Open Access
- 8 November 2021
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (3) , e935-e946
Abstract
Objective To evaluate the role of autoantibodies to N-terminally truncated glutamic acid decarboxylase GAD65(96-585) (t-GADA) as a marker for type 1 diabetes (T1D) and to assess the potential human leukocyte antigen (HLA) associations with such autoantibodies. Design In this cross-sectional study combining data from the Finnish Pediatric Diabetes Register, the Type 1 Diabetes Prediction and Prevention study, the DIABIMMUNE study, and the Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity study, venous blood samples from 760 individuals (53.7% males) were analyzed for t-GADA, autoantibodies to full-length GAD65 (f-GADA), and islet cell antibodies. Epitope-specific GAD autoantibodies were analyzed from 189 study participants. Results T1D had been diagnosed in 174 (23%) participants. Altogether 631 (83%) individuals tested positive for f-GADA and 451 (59%) for t-GADA at a median age of 9.0 (range 0.2-61.5) years. t-GADA demonstrated higher specificity (46%) and positive predictive value (30%) for T1D than positivity for f-GADA alone (15% and 21%, respectively). Among participants positive for f-GADA, those who tested positive for t-GADA carried more frequently HLA genotypes conferring increased risk for T1D than those who tested negative for t-GADA (77% vs 53%; P < 0.001). Conclusions Autoantibodies to N-terminally truncated GAD improve the screening for T1D compared to f-GADA and may facilitate the selection of participants for clinical trials. HLA class II-mediated antigen presentation of GAD(96–585)-derived or structurally similar peptides might comprise an important pathomechanism in T1D.Keywords
Funding Information
- Juvenile Diabetes Research Foundation (1-SRA-2016-342-M-R, 1-SRA-2019-732-M-B)
- European Union (BMH4-CT98-3314, FP7/2007-2013, 202063)
This publication has 45 references indexed in Scilit:
- Extended Family History of Type 1 Diabetes and Phenotype and Genotype of Newly Diagnosed ChildrenDiabetes Care, 2013
- Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trialThe Lancet, 2011
- Evidence for Molecular Mimicry between Human T Cell Epitopes in Rotavirus and Pancreatic Islet AutoantigensThe Journal of Immunology, 2010
- Predictive Characteristics of Diabetes-Associated Autoantibodies Among Children With HLA-Conferred Disease Susceptibility in the General PopulationDiabetes, 2009
- GAD Treatment and Insulin Secretion in Recent-Onset Type 1 DiabetesNew England Journal of Medicine, 2008
- The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetesProceedings of the National Academy of Sciences, 2007
- GAD Autoantibody Affinity and Epitope Specificity Identify Distinct Immunization Profiles in Children at Risk for Type 1 DiabetesDiabetes, 2007
- GAD65 antibody isotypes and epitope recognition during the prediabetic process in siblings of children with type I diabetesClinical and Experimental Immunology, 2004
- Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes.Journal of Clinical Investigation, 1994
- Measuring the Accuracy of Diagnostic SystemsScience, 1988